Pembrolizumab in patients with gastric cancer and liver metastases: A paradigm shift in immunotherapy

doi:10.4240/wjgs.v16.i11.3391

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (250)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

205

Sum=214

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=26

Nov 27, 2024 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastrointest Surg. Nov 27, 2024; 16(11): 3391-3394
Published online Nov 27, 2024. doi: 10.4240/wjgs.v16.i11.3391

Pembrolizumab in patients with gastric cancer and liver metastases: A paradigm shift in immunotherapy

Grigorios Christodoulidis, Dimitra Bartzi, Konstantinos Eleftherios Koumarelas, Marina Nektaria Kouliou

Grigorios Christodoulidis, Department of General Surgery, The University Hospital of Larissa, The University of Thessaly, Larissa 41110, Greece

Dimitra Bartzi, Department of Oncology, The 251 Airforce General Hospital, Athens 11525, Greece

Konstantinos Eleftherios Koumarelas, Department of Emergency Medicine, The General Hospital of Larissa, Larissa 41221, Greece

Marina Nektaria Kouliou, Department of General Surgery, The University Hospital of Larissa, Larissa 41110, Greece

Author contributions: Christodoulidis G, Bartzi D, Koumarelas KE, and Kouliou MN contributed to the discussion, design of the manuscript, the writing and editing of the manuscript, and review of the literature; Christodoulidis G designed the overall concept and outline of the manuscript; all authors have read and agreed to the published version of the manuscript.

Conflict-of-interest statement: We declare no conflict of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Grigorios Christodoulidis, MD, PhD, Academic Editor, Department of General Surgery, University Hospital of Larissa, The University of Thessaly, Biopolis Campus, Larissa 41110, Greece. gregsurg09@gmail.com

Received: April 27, 2024
Revised: July 18, 2024
Accepted: July 24, 2024
Published online: November 27, 2024
Processing time: 185 Days and 23.8 Hours

Core Tip

Core Tip: Given the multifaceted challenges of treating gastric cancer with liver metastases, adopting a personalized approach to therapy is crucial. This involves integrating biomarker testing, such as programmed cell death ligand 1 expression, into treatment decisions to identify likely responders to immunotherapy such as pembrolizumab. By tailoring treatment strategies based on individual patient characteristics and disease biology, clinicians can optimize therapeutic efficacy and mitigate potential adverse events, ultimately improving outcomes for patients navigating this complex clinical scenario.